TY - JOUR
T1 - Biomimetic Nanomedicine Coupled with Neoadjuvant Chemotherapy to Suppress Breast Cancer Metastasis via Tumor Microenvironment Remodeling
AU - Liu, Hai jun
AU - Wang, Junfeng
AU - Wang, Mingming
AU - Wang, Yuzhen
AU - Shi, Shanshan
AU - Hu, Xiangxiang
AU - Zhang, Quanguang
AU - Fan, Daping
AU - Xu, Peisheng
N1 - Funding Information:
The authors want to thank National Institutes of Health (1R01AG054839‐01A1, 1R41CA254500‐01A1, and 1R21CA252360‐01) for financial support for the research. The experiments were approved by the Institutional Animal Care and Use Committee of the University of South Carolina (2412‐101315‐032818).
Funding Information:
The authors want to thank National Institutes of Health (1R01AG054839-01A1, 1R41CA254500-01A1, and 1R21CA252360-01) for financial support for the research. The experiments were approved by the Institutional Animal Care and Use Committee of the University of South Carolina (2412-101315-032818).
Publisher Copyright:
© 2021 Wiley-VCH GmbH
PY - 2021/6/16
Y1 - 2021/6/16
N2 - The biomimetic enzyme activity of cerium oxide nanoparticles (CeNPs) prefers ultrasmall particle size and bare surface. Unfortunately, those two features are not favorable for its in vivo application due to easy aggregation and fast renal filtration. To take advantage of the activity of CeNP for cancer therapy, a homologous targeted cerium oxide nanoparticle system, targeted CeNP (T-CeNP), with the integration of a biodegradable dendritic mesoporous silica nanoparticle, superoxide dismutase and catalase mimicking CeNPs, and the camouflage coating of cancer cell membrane has been developed. Attributed to the homologous targeting effect of cancer cell membrane, nanoparticles with camouflage coating are retained in the tumor in an orthotopic breast cancer metastatic model. Subsequently, T-CeNP effectively hinders cancer-associated fibroblast transdifferentiation and reprograms it back to a normal fibroblast. Consequently, T-CeNP coupled with doxorubicin reduces the size of primary tumors and prevents the post-surgery lung metastasis and liver metastasis of breast cancer.
AB - The biomimetic enzyme activity of cerium oxide nanoparticles (CeNPs) prefers ultrasmall particle size and bare surface. Unfortunately, those two features are not favorable for its in vivo application due to easy aggregation and fast renal filtration. To take advantage of the activity of CeNP for cancer therapy, a homologous targeted cerium oxide nanoparticle system, targeted CeNP (T-CeNP), with the integration of a biodegradable dendritic mesoporous silica nanoparticle, superoxide dismutase and catalase mimicking CeNPs, and the camouflage coating of cancer cell membrane has been developed. Attributed to the homologous targeting effect of cancer cell membrane, nanoparticles with camouflage coating are retained in the tumor in an orthotopic breast cancer metastatic model. Subsequently, T-CeNP effectively hinders cancer-associated fibroblast transdifferentiation and reprograms it back to a normal fibroblast. Consequently, T-CeNP coupled with doxorubicin reduces the size of primary tumors and prevents the post-surgery lung metastasis and liver metastasis of breast cancer.
KW - cancer metastasis
KW - cancer-associated fibroblast
KW - cerium oxide nanoparticle
KW - homologous targeting
KW - tumor microenvironment
UR - http://www.scopus.com/inward/record.url?scp=85103387998&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103387998&partnerID=8YFLogxK
U2 - 10.1002/adfm.202100262
DO - 10.1002/adfm.202100262
M3 - Article
AN - SCOPUS:85103387998
SN - 1616-301X
VL - 31
JO - Advanced Functional Materials
JF - Advanced Functional Materials
IS - 25
M1 - 2100262
ER -
